Using better and new generation ALK‐TKIs on a priority basis could improve the prognosis of ALK‐positive NSCLC patients, and the mechanism responsible for the short PFS of sensitive ALK‐TKI to secondary mutation should be clarified. The gene discussed is ALK; the disease is non-small cell lung carcinoma.